Literature DB >> 19969080

Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.

Michele M Castro1, Elen Rizzi, Cibele M Prado, Marcos A Rossi, Jose E Tanus-Santos, Raquel Fernanda Gerlach.   

Abstract

Structural vascular changes in two-kidney, one-clip (2K-1C) hypertension may result from increased matrix metalloproteinase (MMP)-2 activity. MMP-2 activation is regulated by other MMPs, including transmembrane-MMPs, and by tissue inhibitors of MMPs (TIMPs). We have investigated the localization of MMP-2, -9, -14, and TIMPs 1-4 in hypertensive aortas and measured their levels by zymography/Western blotting and immunohistochemistry. Gelatinolytic activity was assayed in tissues by in situ zymography. Sham-operated and 2K-1C hypertensive rats were treated with doxycycline (or vehicle) for 8 weeks, and the systolic blood pressure was monitored weekly. Doxycycline attenuated 2K-1C hypertension (165 + or - 11.7 mmHg versus 213 + or - 7.9 mm Hg in hypertensive controls, P<0.01), and completely prevented increase in the thicknesses of the media and the intima in 2K-1C animals (P<0.01). Increased amounts of MMP-2, -9, and -14 were found in hypertensive aortas, as well as enhanced gelatinolytic activity. A gradient in the localization of MMP-2, -9, and -14 was found, with increased amounts detected in the intima, at sites with higher gelatinolytic activity. Doxycycline attenuated hypertension induced increases in all the 3 investigated MMPs in both the media and the intima (all P<0.05), but it did not change the amounts of TIMPs 1-4 (P>0.05). Therefore, an imbalance between increased amounts of MMPs at the tissue level without a corresponding increase in the quantities of TIMPs, particularly in the intima and inner media layers, appears to account for the increased proteolytic activity found in 2K-1C hypertension-induced maladaptive vascular remodeling. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969080     DOI: 10.1016/j.matbio.2009.11.005

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  30 in total

1.  Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli.

Authors:  Andrezza N Gonçalves; Cesar A Meschiari; William G Stetler-Stevenson; M Cristina Nonato; Cleidson P Alves; Enilza M Espreafico; Raquel F Gerlach
Journal:  J Biotechnol       Date:  2011-10-05       Impact factor: 3.307

2.  Endogenous nitric oxide formation correlates negatively with circulating matrix metalloproteinase (MMP)-2 and MMP-9 levels in black subjects.

Authors:  Ingrid F Metzger; Valéria C Sandrim; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

Review 5.  Angiotensin II and vascular injury.

Authors:  Augusto C Montezano; Aurelie Nguyen Dinh Cat; Francisco J Rios; Rhian M Touyz
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

Review 6.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

7.  Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.

Authors:  Diogo M O Marçal; Elen Rizzi; Alisson Martins-Oliveira; Carla S Ceron; Danielle A Guimaraes; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-31       Impact factor: 3.000

8.  Nitric oxide attenuates matrix metalloproteinase-9 production by endothelial cells independent of cGMP- or NFκB-mediated mechanisms.

Authors:  Cesar A Meschiari; Tatiane Izidoro-Toledo; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2013-03-03       Impact factor: 3.396

9.  Sodium nitrite attenuates MMP-9 production by endothelial cells and may explain similar effects of atorvastatin.

Authors:  Cesar A Meschiari; Lucas C Pinheiro; Danielle A Guimaraes; Raquel F Gerlach; Jose E Tanus-Santos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-11-28       Impact factor: 3.000

Review 10.  Matrix metalloproteinases as drug targets in preeclampsia.

Authors:  Ana C T Palei; Joey P Granger; Jose E Tanus-Santos
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.